Objective To evaluate onset of effect of galcanezumab in patients with episodic migraine.
Background Galcanezumab is a monoclonal antibody that binds to calcitonin gene‐related …

Objective To characterize adult patients with episodic migraine who achieved 100%
response to galcanezumab treatment. Background Galcanezumab is a humanized …

Introduction Galcanezumab is a humanized monoclonal antibody binding calcitonin gene-
related peptide, used for migraine prevention. Methods A global, double-blind, 6-month …

Background Galcanezumab is a monoclonal antibody (mAb) that binds calcitonin gene-
related peptide (CGRP) and is indicated for the preventive treatment of migraine …

Background Galcanezumab, a monoclonal antibody to calcitonin gene-related peptide, was
found to be safe and efficacious for the preventive treatment of chronic migraine based on …

Background Galcanezumab, a humanized monoclonal antibody that selectively binds to
calcitonin gene-related peptide, has demonstrated a significant reduction in monthly …

Background Galcanezumab, a humanized monoclonal antibody that binds calcitonin gene-
related peptide, has demonstrated a significant reduction in monthly migraine headache …

Background The phase 3 randomized PERSIST study demonstrated the efficacy and
tolerability of galcanezumab, a humanized anti-calcitonin gene-related peptide (CGRP) …

Background and purpose The efficacy of galcanezumab, a monoclonal antibody for
migraine prevention, has been demonstrated in two pivotal trials in patients with episodic …

Background Maintenance of effect following treatment with galcanezumab compared to
placebo in adult patients with episodic or chronic migraine was evaluated. Methods In 2 …